Coronation Fund Managers Ltd. Raises Holdings in Elevance Health, Inc. $ELV

Key Points

• Coronation Fund Managers raised its stake in Elevance Health by 24.9%, now owning 159,249 shares worth about $55.8 million, making ELV its 11th-largest holding.
• Elevance beat Q1 estimates with $12.58 EPS (vs. $10.74 est.), raised its 2026 adjusted EPS outlook to at least $26.75, and attracted bullish analyst moves including Sanford Bernstein's $424 price target.
• Investors face heightened risk from a new securities probe by law firm Kirby McInerney, while the company also announced a quarterly dividend of $1.72 (annualized $6.88, ~2.0% yield; ex-dividend June 10).

Coronation Fund Managers Ltd. grew its position in Elevance Health, Inc. (NYSE:ELV - Free Report) by 24.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 159,249 shares of the company's stock after buying an additional 31,754 shares during the quarter. Elevance Health accounts for 2.5% of Coronation Fund Managers Ltd.'s holdings, making the stock its 11th largest holding. Coronation Fund Managers Ltd. owned about 0.07% of Elevance Health worth $55,825,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Physician Wealth Advisors Inc. lifted its holdings in shares of Elevance Health by 331.6% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company's stock worth $26,000 after buying an additional 63 shares during the period. Activest Wealth Management lifted its stake in shares of Elevance Health by 66.7% during the 3rd quarter. Activest Wealth Management now owns 85 shares of the company's stock worth $27,000 after purchasing an additional 34 shares during the last quarter. Rossby Financial LCC lifted its stake in shares of Elevance Health by 110.0% during the 3rd quarter. Rossby Financial LCC now owns 84 shares of the company's stock worth $28,000 after purchasing an additional 44 shares during the last quarter. Motco lifted its stake in shares of Elevance Health by 334.8% during the 3rd quarter. Motco now owns 100 shares of the company's stock worth $32,000 after purchasing an additional 77 shares during the last quarter. Finally, True Wealth Design LLC lifted its stake in shares of Elevance Health by 431.8% during the 3rd quarter. True Wealth Design LLC now owns 117 shares of the company's stock worth $38,000 after purchasing an additional 95 shares during the last quarter. 89.24% of the stock is currently owned by hedge funds and other institutional investors.

Elevance Health News Summary

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Q1 beat and upgraded outlook — ELV reported strong Q1 results (EPS $12.58 vs. estimates) and raised its 2026 adjusted EPS outlook to at least $26.75 while targeting ~12% EPS growth in 2027, which supports earnings upside and margin improvement. Elevance raises 2026 outlook
• Positive Sentiment: Large analyst upgrade — Sanford C. Bernstein raised its price target to $424 and kept an "outperform" rating, implying ~23% upside; a high-conviction bullish call that can attract demand. Bernstein raises PT to $424
• Positive Sentiment: Barclays reiteration of Buy — Barclays stuck with a Buy rating, signaling institutional confidence that can provide support for the shares. Barclays sticks to Buy
• Positive Sentiment: Operational tailwinds noted — Management highlighted medical cost controls and AI-driven margin expansion, and major outlets reported the company raised its annual profit forecast on those controls, reinforcing the positive earnings message. Profit forecast raised on cost controls
• Neutral Sentiment: Mixed analyst PT lifts with conservative ratings — Several firms nudged up targets but kept neutral/hold stances (Goldman to $370 neutral; Deutsche Bank to $363 hold; Evercore to $360 in-line). These raise reference prices but signal measured optimism. Goldman raises PT to $370
• Neutral Sentiment: Jefferies update — Jefferies revised its forecasts after a deeper look at exchange-segment dynamics and trimmed its PT slightly; this is an analyst reshuffle rather than a directional shock. Jefferies updates forecasts
• Negative Sentiment: Investor litigation probe — Law firm Kirby McInerney has opened an investigation into potential securities claims involving Elevance and/or its senior management; legal scrutiny can pressure the stock and raise uncertainty. Kirby McInerney investor alert
• Negative Sentiment: Some broker nuance implies limited near-term upside — Robert W. Baird's update leaves a neutral stance with a lower relative target vs. some peers, noting limited immediate upside which can cap buying interest. Baird adjusts PT

Elevance Health Trading Down 0.5%

Shares of NYSE:ELV opened at $344.64 on Friday. The business's 50-day moving average is $308.96 and its 200 day moving average is $331.62. Elevance Health, Inc. has a 1 year low of $273.71 and a 1 year high of $427.54. The firm has a market capitalization of $74.84 billion, a P/E ratio of 14.66, a P/E/G ratio of 1.84 and a beta of 0.49. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.48 and a quick ratio of 1.54.

Elevance Health (NYSE:ELV - Get Free Report) last announced its quarterly earnings data on Wednesday, April 22nd. The company reported $12.58 earnings per share for the quarter, beating analysts' consensus estimates of $10.74 by $1.84. The business had revenue of $49.49 billion for the quarter, compared to analyst estimates of $48.21 billion. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The company's revenue was up 1.5% on a year-over-year basis. During the same period in the prior year, the company earned $11.97 earnings per share. Elevance Health has set its FY 2026 guidance at 19.850- EPS. On average, research analysts predict that Elevance Health, Inc. will post 26.79 earnings per share for the current fiscal year.

Elevance Health Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 25th. Stockholders of record on Wednesday, June 10th will be issued a $1.72 dividend. The ex-dividend date of this dividend is Wednesday, June 10th. This represents a $6.88 dividend on an annualized basis and a dividend yield of 2.0%. Elevance Health's dividend payout ratio is currently 27.39%.

Analysts Set New Price Targets

ELV has been the subject of a number of analyst reports. Deutsche Bank Aktiengesellschaft upped their price objective on Elevance Health from $332.00 to $363.00 and gave the stock a "hold" rating in a research note on Thursday. Robert W. Baird upped their price objective on Elevance Health from $317.00 to $331.00 and gave the stock a "neutral" rating in a research note on Thursday. Barclays upped their price objective on Elevance Health from $393.00 to $408.00 and gave the stock an "overweight" rating in a research note on Friday. Truist Financial decreased their price objective on Elevance Health from $390.00 to $375.00 and set a "buy" rating for the company in a research note on Monday, April 13th. Finally, Guggenheim upped their price objective on Elevance Health from $396.00 to $399.00 and gave the stock a "buy" rating in a research note on Friday. Eleven research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Elevance Health presently has a consensus rating of "Hold" and an average target price of $380.42.

Elevance Health Profile

Elevance Health, Inc NYSE: ELV is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company's strategic focus on integrated health care and benefit delivery.

Elevance's core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.